Cansino Bio Gets Approval for Polio Vaccine Trial in Indonesia

MT Newswires Live10-09

Cansino Biologics (HKG:6185) has obtained approval in Indonesia for its phase I/II clinical trial of CS-2036, a recombinant poliomyelitis vaccine.

CS-2036 is a polio VLP vaccine with good safety and immunogenicity profiles, according to a Wednesday filing with the Hong Kong Exchange.

The clinical trials will further evaluate the safety and immunogenicity of CS-2036 in infants and toddlers at certain ages, the filing stated.

Shares of the Chinese biotechnology company closed over 8% lower on Wednesday.

Price (HKD): $26.10, Change: $-2.3, Percent Change: -8.10%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474248135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-09 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474248135","market":"nz","top_or_hot":-1,"title":"Cansino Bio Gets Approval for Polio Vaccine Trial in Indonesia","media":"MT Newswires Live","content":"<html><body><p> Cansino Biologics (HKG:6185) has obtained approval in Indonesia for its phase I/II clinical trial of CS-2036, a recombinant poliomyelitis vaccine.</p><p>CS-2036 is a polio VLP vaccine with good safety and immunogenicity profiles, according to a Wednesday filing with the Hong Kong Exchange.</p><p>The clinical trials will further evaluate the safety and immunogenicity of CS-2036 in infants and toddlers at certain ages, the filing stated.</p><p>Shares of the Chinese biotechnology company closed over 8% lower on Wednesday.</p><p>Price (HKD): $26.10, Change: $-2.3, Percent Change: -8.10%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cansino Bio Gets Approval for Polio Vaccine Trial in Indonesia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCansino Bio Gets Approval for Polio Vaccine Trial in Indonesia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cansino Biologics (HKG:6185) has obtained approval in Indonesia for its phase I/II clinical trial of CS-2036, a recombinant poliomyelitis vaccine.CS-2036 is a polio VLP vaccine with good safety and ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2474248135","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474248135","pubTimestamp":1728471190,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cansino Biologics  has obtained approval in Indonesia for its phase I/II clinical trial of CS-2036, a recombinant poliomyelitis vaccine.CS-2036 is a polio VLP vaccine with good safety and immunogenicity profiles, according to a Wednesday filing with the Hong Kong Exchange.The clinical trials will further evaluate the safety and immunogenicity of CS-2036 in infants and toddlers at certain ages, the filing stated.Shares of the Chinese biotechnology company closed over 8% lower on Wednesday.Price : $26.10, Change: $-2.3, Percent Change: -8.10%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股","BK4526":"热门中概股","BK4588":"碎股","BK4023":"应用软件","06185":"康希诺生物"},"translate_title":"康希诺生物获得印尼脊髓灰质炎疫苗试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":0.9},"content_text":"Cansino Biologics (HKG:6185) has obtained approval in Indonesia for its phase I/II clinical trial of CS-2036, a recombinant poliomyelitis vaccine.CS-2036 is a polio VLP vaccine with good safety and immunogenicity profiles, according to a Wednesday filing with the Hong Kong Exchange.The clinical trials will further evaluate the safety and immunogenicity of CS-2036 in infants and toddlers at certain ages, the filing stated.Shares of the Chinese biotechnology company closed over 8% lower on Wednesday.Price (HKD): $26.10, Change: $-2.3, Percent Change: -8.10%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474248135"}